X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (319) 319
Publication (126) 126
Paper (95) 95
Patent (73) 73
Book / eBook (14) 14
Report (14) 14
Book Chapter (4) 4
Conference Proceeding (4) 4
Book Review (3) 3
Dissertation (3) 3
Newspaper Article (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
physics (173) 173
experiment (113) 113
index medicus (106) 106
humans (98) 98
high energy physics - experiment (96) 96
particle physics (92) 92
female (83) 83
oncology (79) 79
high energy physics (78) 78
physics - high energy physics - experiment (74) 74
middle aged (71) 71
chemical or physical laboratory apparatus for general use (70) 70
performing operations (70) 70
physical or chemical processes or apparatus in general (70) 70
transporting (70) 70
adult (68) 68
aged (67) 67
investigating or analysing materials by determining theirchemical or physical properties (64) 64
measuring (64) 64
testing (64) 64
particle physics - experiment (56) 56
physics of elementary particles and fields (56) 56
cancer (48) 48
chemical or physical processes, e.g. catalysis or colloidchemistry (46) 46
hadron-hadron scattering (46) 46
hematology, oncology and palliative medicine (46) 46
obstetrics & gynecology (46) 46
their relevant apparatus (46) 46
article (45) 45
obstetrics and gynecology (43) 43
chemistry (42) 42
microbiology (42) 42
nuclear experiment (42) 42
vinegar (42) 42
beer (41) 41
biochemistry (41) 41
compositions or test papers therefor (41) 41
condition-responsive control in microbiological orenzymological processes (41) 41
enzymology (41) 41
measuring or testing processes involving enzymes, nucleicacids or microorganisms (41) 41
metallurgy (41) 41
mutation or genetic engineering (41) 41
processes of preparing such compositions (41) 41
spirits (41) 41
wine (41) 41
aged, 80 and over (39) 39
phenomenology (38) 38
physics, particles & fields (38) 38
general tagging of cross-sectional technologies spanning over several sections of the ipc (36) 36
general tagging of new technological developments (36) 36
technical subjects covered by former us classification (36) 36
technical subjects covered by former uspc (36) 36
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (36) 36
research (34) 34
cms (33) 33
neoplasm recurrence, local - drug therapy (32) 32
elementary particles, quantum field theory (31) 31
quantum field theories, string theory (31) 31
analysis (30) 30
care and treatment (30) 30
clinical trials (30) 30
classical and quantum gravitation, relativity theory (28) 28
combinatorial chemistry (28) 28
derivatives thereof (28) 28
libraries, e.g. chemical libraries, in silicolibraries (28) 28
mixing, e.g. dissolving, emulsifying, dispersing (28) 28
nucleic acids (28) 28
nucleosides (28) 28
nucleotides (28) 28
organic chemistry (28) 28
quantum physics (28) 28
sugars (28) 28
chemotherapy (26) 26
disease-free survival (26) 26
male (26) 26
cern lhc coll (24) 24
experimental results (24) 24
ovarian neoplasms - drug therapy (24) 24
carcinoma (23) 23
peritoneal neoplasms - drug therapy (23) 23
oncology, experimental (22) 22
7000 gev-cms (21) 21
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (20) 20
astrophysics (19) 19
ovarian cancer (18) 18
física (17) 17
instrumentation and detectors (17) 17
astronomy & astrophysics (16) 16
bevacizumab (16) 16
cisplatin (16) 16
high energy astrophysical phenomena (16) 16
paclitaxel (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
dna methylation (14) 14
p p: interaction (14) 14
tumors (14) 14
angiogenesis inhibitors - therapeutic use (13) 13
antimitotic agents (13) 13
antineoplastic agents (13) 13
antineoplastic agents - therapeutic use (13) 13
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
St. Augustine's Seminary - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
UofT at Scarborough - Stacks (2) 2
Art - Library use only (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Criminology - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Knox College (Caven) - Stacks (1) 1
Map & Data - Map Collection (1) 1
Online Resources - Online (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Royal Ontario Museum - Far Eastern (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2014, Volume 370, Issue 8, pp. 734 - 743
Journal Article
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 3, pp. 386 - 391
Abstract Background Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2 . We... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA1, BRCA2 mutation | Toxicity | Veliparib | PARP inhibitor | Phase II trial | Ovarian cancer | SENSITIVITY | OPEN-LABEL | COMBINATION | PLATINUM-FREE INTERVAL | SOMATIC MUTATIONS | OBSTETRICS & GYNECOLOGY | OLAPARIB | ONCOLOGY | RESISTANCE | HOMOLOGOUS RECOMBINATION | REFRACTORY SOLID TUMORS | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Peritoneal Neoplasms - genetics | Fallopian Tube Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Genes, BRCA1 | Benzimidazoles - adverse effects | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Benzimidazoles - therapeutic use | Fallopian Tube Neoplasms - drug therapy | Medical research | Cancer patients | Care and treatment | Gene mutations | Analysis | Medicine, Experimental | Genetic aspects | Cancer | Chemotherapy | Clinical trials | Index Medicus | toxicity | BRCA2 mutation | ovarian cancer | veliparib | BRCA1
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 07/2010, Volume 118, Issue 1, pp. 96 - 97
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2012, Volume 127, Issue 3, pp. 538 - 543
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2011, Volume 123, Issue 1, pp. 19 - 26
Abstract Objective Patients with persistent/recurrent epithelial ovarian cancer/primary peritoneal cancer (EOC/PPC) have limited treatment options. AKT and... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | mTOR inhibitor | Circulating tumor cells | Ovarian clinical trial | AKT/PI3K pathway | MAMMALIAN TARGET | CARCINOMA PATIENTS | REFRACTORY OVARIAN | PERIPHERAL-BLOOD | METASTATIC COLORECTAL-CANCER | PLATINUM-RESISTANT | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | ONCOLOGY | THERAPEUTIC TARGET | RESISTANT PROSTATE-CANCER | DISEASE PROGRESSION | TOR Serine-Threonine Kinases - metabolism | Peritoneal Neoplasms - blood | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasms, Glandular and Epithelial - metabolism | Antineoplastic Agents - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Neoplasms, Glandular and Epithelial - blood | Peritoneal Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Ovarian Neoplasms - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Ovarian Neoplasms - drug therapy | Sirolimus - adverse effects | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Neoplastic Cells, Circulating - drug effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Ovarian Neoplasms - blood | Cyclin D1 - biosynthesis | Disease-Free Survival | Peritoneal Neoplasms - metabolism | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Aged | Antimitotic agents | Relapse | Care and treatment | Clinical trials | Product development | Metastasis | Antineoplastic agents | Diseases | Cancer | Index Medicus | PI3K pathway | AKT | ovarian clinical trial
Journal Article